{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:16:37Z","timestamp":1793286997069,"version":"4.5.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"25","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Dysregulated immune function in rheumatoid arthritis (RA) might lead to the development of myelodysplastic syndrome (MDS). Serum interleukin-6 (IL-6) concentrations are increased in both RA and MDS patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 58-year-old woman presented with severe RA. During a recent 8-month period, the patient experienced swelling in multiple joints, dizziness, and severe anemia. The symptoms responded poorly to oral corticosteroids and methotrexate (MTX). Even treatment of the patient's anemia by transfusion of red blood cells was ineffective. Laboratory tests showed high levels of IL-6 (214.24\u200apg\/mL).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>Combining her medical history with clinical and laboratory parameters, especially those obtained by bone marrow aspiration, a diagnosis of RA with MDS was made.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>MTX was discontinued and the patient was given tocilizumab intravenously at a dose of 8 mg\/kg every 4 weeks and oral corticosteroids (15\u200amg\/QD).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The patient's serological, physical, and pathological abnormalities improved significantly.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>We report a case of RA with MDS successfully treated with tocilizumab. To our knowledge, this is the first case of an RA patient with MDS that was successfully treated with tocilizumab. In addition, our case emphasizes that IL-6 plays a critical role in the pathogenesis of RA with MDS. Tocilizumab might be an effective treatment for RA with MDS, especially in those with high levels of IL-6, elevated C-reactive protein, and severe anemia.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000011179","type":"journal-article","created":{"date-parts":[[2018,6,20]],"date-time":"2018-06-20T21:57:01Z","timestamp":1529531821000},"page":"e11179","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Usefulness of tocilizumab for treating rheumatoid arthritis with myelodysplastic syndrome"],"prefix":"10.1097","volume":"97","author":[{"given":"Chuanyin","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingwan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanhua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-64-20250418","first-page":"5","article-title":"The pathogenesis of rheumatoid arthritis","volume":"36","author":"Koch","year":"2007","journal-title":"Am J Orthop"},{"key":"R2-64-20250418","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/art.23940","article-title":"Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study","volume":"58","author":"Genovese","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R3-64-20250418","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1172\/JCI200420945","article-title":"IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin","volume":"113","author":"Nemeth","year":"2004","journal-title":"J Clin Invest"},{"key":"R4-64-20250418","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/leu.2014.325","article-title":"Myelodysplasia is in the niche: novel concepts and emerging therapies","volume":"29","author":"Bulycheva","year":"2015","journal-title":"Leukemia"},{"key":"R5-64-20250418","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1445-5994.1996.tb02940.x","article-title":"Rheumatic manifestations of the myelodysplastic syndromes: a comparative study","volume":"26","author":"Chandran","year":"1996","journal-title":"Aust N Z J Med"},{"key":"R6-64-20250418","first-page":"22","article-title":"Inflammatory rheumatologic disorders in patients with myelodysplastic syndromes: a cross-sectional study","volume":"9","author":"Mobini","year":"2015","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"key":"R7-64-20250418","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MD.0000000000000011","article-title":"Inflammatory arthritis in patients with myelodysplastic syndromes: a multicenter retrospective study and literature review of 68 cases","volume":"93","author":"Mekinian","year":"2014","journal-title":"Medicine"},{"key":"R8-64-20250418","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1159\/000065722","article-title":"Circulating levels of thrombopoietic and inflammatory cytokines in patients with acute myeloblastic leukemia and myelodysplastic syndrome","volume":"63","author":"Hsu","year":"2002","journal-title":"Oncology"},{"key":"R9-64-20250418","first-page":"676","article-title":"Myelodysplastic syndromes and acute myeloid leukemia in connective tissue disease after single-agent chemotherapy","volume":"106","author":"Rosenthal","year":"1996","journal-title":"Am J ClinPathol"},{"key":"R10-64-20250418","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0049-0172(92)90035-C","article-title":"Seronegative inflammatory arthritis in the myelodysplastic syndromes","volume":"21","author":"George","year":"1992","journal-title":"Semin Arthritis Rheum"},{"key":"R11-64-20250418","first-page":"30","article-title":"[A case of malignant rheumatoid arthritis associated with myelodysplastic syndrome]","volume":"37","author":"Hisakawa","year":"1997","journal-title":"Ryumachi"},{"key":"R12-64-20250418","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3346\/jkms.1999.14.3.319","article-title":"Rheumatoid arthritis associated with myelodysplastic syndrome: a case report","volume":"14","author":"Nam","year":"1999","journal-title":"J Korean Med Sci"},{"key":"R13-64-20250418","doi-asserted-by":"crossref","first-page":"121","DOI":"10.5387\/fms.56.121","article-title":"Therapy-related myelodysplastic syndrome following cyclophosphamide pulse and\/or methotrexate therapy in a patient with systemic lupus erythematosus","volume":"56","author":"Iwadate","year":"2010","journal-title":"Fukushima J Med Sci"},{"key":"R14-64-20250418","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/03009740600844506","article-title":"Rheumatoid arthritis patients with therapy-induced myelodysplastic syndrome present with long-term remission after recovery","volume":"36","author":"Thonhofer","year":"2007","journal-title":"Scand J Rheumatol"},{"key":"R15-64-20250418","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1345\/aph.1D117","article-title":"Myelodysplastic syndrome associated with low-dose methotrexate in rheumatoid arthritis","volume":"38","author":"Okamoto","year":"2004","journal-title":"Ann Pharmacother"},{"key":"R16-64-20250418","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1345\/aph.1E274","article-title":"Progression of myelodysplasia during low-dose methotrexate therapy in rheumatoid arthritis","volume":"38","author":"Murphy","year":"2004","journal-title":"Ann Pharmacother"},{"key":"R17-64-20250418","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MD.0000000000000011","article-title":"Inflammatory arthritis in patients with myelodysplastic syndromes: a multicenter retrospective study and literature review of 68 cases","volume":"93","author":"Mekinian","year":"2014","journal-title":"Medicine (Baltimore"},{"key":"R18-64-20250418","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1159\/000065722","article-title":"Circulating levels of thrombopoietic and inflammatory cytokines in patients with acute myeloblastic leukemia and myelodysplastic syndrome","volume":"63","author":"Hsu","year":"2002","journal-title":"Oncology"},{"key":"R19-64-20250418","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1023\/A:1012559724283","article-title":"In vivo production of cytokines by bone marrow stromal cells and macrophages from patients with myelodysplastic syndrome","volume":"132","author":"Manakova","year":"2001","journal-title":"Bull ExpBiol Med"},{"key":"R20-64-20250418","doi-asserted-by":"crossref","first-page":"E156","DOI":"10.1002\/ajh.23780","article-title":"A phase 2, randomized, double-blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low- or intermediate-1\u2013risk myelodysplastic syndrome","volume":"89","author":"Garcia-Manero","year":"2014","journal-title":"Am J Hematol"},{"key":"R21-64-20250418","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1136\/annrheumdis-2013-203523","article-title":"Extended report: A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)","volume":"73","author":"Burmester","year":"2014","journal-title":"Ann Rheum Dis"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201806220-00064","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T14:01:32Z","timestamp":1744984892000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201806220-00064"}},"subtitle":["A case report and literature review"],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":21,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000011179","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]}}}